|Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study|
LA Carey, CM Perou, CA Livasy, LG Dressler, D Cowan, K Conway, ...
Jama 295 (21), 2492-2502, 2006
|Supervised risk predictor of breast cancer based on intrinsic subtypes|
JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ...
Journal of clinical oncology 27 (8), 1160, 2009
|Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma|
TO Nielsen, FD Hsu, K Jensen, M Cheang, G Karaca, Z Hu, ...
Clinical cancer research 10 (16), 5367-5374, 2004
|Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer|
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
|Metastatic behavior of breast cancer subtypes|
H Kennecke, R Yerushalmi, R Woods, MCU Cheang, D Voduc, ...
Journal of clinical oncology 28 (20), 3271-3277, 2010
|Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype|
MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ...
Clinical cancer research 14 (5), 1368-1376, 2008
|Breast cancer subtypes and the risk of local and regional relapse|
KD Voduc, MCU Cheang, S Tyldesley, K Gelmon, TO Nielsen, ...
Journal of clinical oncology 28 (10), 1684-1691, 2010
|Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 …|
FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ...
PLoS medicine 7 (5), e1000279, 2010
|Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer|
I Garcia-Murillas, G Schiavon, B Weigelt, C Ng, S Hrebien, RJ Cutts, ...
Science translational medicine 7 (302), 302ra133-302ra133, 2015
|A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast CancerPAM50 in ER …|
TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ...
Clinical cancer research 16 (21), 5222-5232, 2010
|Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial|
J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ...
Journal of clinical oncology 27 (8), 1168, 2009
|Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer|
A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ...
Journal of clinical oncology 31 (2), 203, 2013
|Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer|
A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou
The oncologist 18 (2), 123-133, 2013
|Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial|
A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ...
Nature medicine 24 (5), 628-637, 2018
|Use of immunohistochemical markers can refine prognosis in triple negative breast cancer|
M Tischkowitz, JS Brunet, LR Bégin, DG Huntsman, MCU Cheang, ...
BMC cancer 7 (1), 1-11, 2007
|Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers|
S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ...
Journal of Clinical Oncology 26 (35), 5697-5704, 2008
|Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)|
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132 (3), 1049-1062, 2012
|Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells|
BW Sutherland, J Kucab, J Wu, C Lee, MCU Cheang, E Yorida, D Turbin, ...
Oncogene 24 (26), 4281-4292, 2005
|Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …|
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542, 2016
|Use of mutation profiles to refine the classification of endometrial carcinomas|
MK McConechy, J Ding, MCU Cheang, KC Wiegand, J Senz, AA Tone, ...
The Journal of pathology 228 (1), 20-30, 2012